NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

A few thoughts here, let me first say this is a brief reply, because I don't claim to have the time to decompact this post, but I find some items interesting.


1. I'm not sure why you did not include the abstract. It was easy to find here: http://www.ejcancer.com/article/S0959-8049(15)00060-X/abstract?cc=y=

2. It's cross-posted at iVillage: http://www.investorvillage.com/smbd.asp?mb=6543&mn=6379&pt=msg&mid=16510416

3. As a quick addition, to my comments below, I note that the article is discussed here as well, but in a more dated, discussion that suggests it is not in the context of pending release of data. I think it's worth reviewing this discussion, though I don't have time to delve into it, I think it's a more positive take on the details here: http://www.siliconinvestor.com/readmsgs.aspx?subjectid=56756&msgnum=633&batchsize=10&batchtype=Next

And I'm not sure that anyone who can rebut it will post on both sites. But I would be interested to hear more. I think it's flawed to rebut to an abstract. It's also unfortunate if you don't list which article it actually is and who the authors are, while accusing them of some quite serious either failure in their expertise or fraud.

It seems to me that your quote of the conclusion is not exact, because the conclusion refers to TWO cohorts and you wish to focus only on these 8 patients, out of context:

Results and conclusion
The results obtained in two cohorts of patients with rGBM suggest that treatment with autologous DC pulsed with autologous tumour cell lysate can extend survival by 5 months or more.

http://www.ejcancer.com/article/S0959-8049(15)00060-X/abstract?cc=y=
https://www.researchgate.net/publication/276494898_ITOC2_-_017_Prolonged_survival_for_patients_with_recurrent_glioblastoma_multiforme_who_are_treated_with_tumour_lysate-pulsed_autologous_dendritic_cells

ITOC2 – 017. Prolonged survival for patients with recurrent glioblastoma multiforme who are treated with tumour lysate-pulsed autologous dendritic cells

Bosch L. Marnix, Prins M. Robert, Liau Linda

As a check on the view of other scholars on this article, one might check if it gets citations by other scholars.

Here are more resources:

From NWBIO website: http://www.nwbio.com/AACR_poster_prolonged_survival.pdf
The above linked pdf includes lots more data than you have in your analysis of the abstract, including additional charts and other information. As I said, I'm far too busy today and in the coming days to probably dig into this but, I'd suggest it is well worth further analysis. But it's kind of basic courtesy to include the links so others can evaluate what you're saying and if it is solid or based upon a misunderstanding, etc. Just a request that you please include the link when you post and cross post it so that people can fairly review and analyze what it is that you're saying.

'AVII77' Quote:
If you know something about these 8, please post it.


The Abstract says:
"A second cohort of patients with rGBM consisted of 8 patients with recurrence following several adjuvant temozolomide treatment cycles. Median OS for these patients is 14.7 months from the time of surgery for first recurrence. The comparator for this cohort is derived from Friedman et al. (2009), who reported mOS of 8.7-9.3 months from the time of first recurrence for rGBM patients treated with Bevacizumab with or without Irinotecan"

There are two errors here.

1. The Median OS for these patients was NOT 14.7 months it was 11 months.

2. Their comparator, Friedman 2009, did not report "from the time of first recurrence for rGBM". They reported from the time of randomization (a later timepoint than DCVax's "from the time of surgery". Freidman: "The median OS times from the time of random assignment were 9.2 months for the BV group and 8.7 months for the BV + CPT-11 group"



The Abstract conclusion says:
"These results suggest that treatment with DCVax-L can extend survival by 5 months or more in patients with rGBM."

And it should say:
"These results suggest that treatment with DCVax-L can extend survival by zero months in patients with rGBM"

But the good news for longs is that they don't have to worry about cross-over confounding the ITT OS analysis because this data suggests that DCVax doesn't do Jack in that population.

I wonder if that will make it into MD1225's upcoming SA article.

These people have, IMO, no business running a clinical trial in human subjects until they can:
1. Correctly design a trial,
2. Correctly assess the results of the trial,
3. Correctly interpret those results, and
4. Correctly report those results.

(Good luck responding to that w/o violating the TOS)

Finally, we have all lost loved ones to cancer. And we will lose more. It turns my stomach to think of the hundreds of millions of dollars that went into this program. And don't kid yourself, that money was diverted from other projects; as a society we only have so much to spend. The Woodford's of this world do not have bottomless pockets. The cure that could save your child could be sitting on a shelf somewhere waiting for the funds to bring it forward.